Primary central nervous system lymphoma: Inter-compartmental progression

被引:4
作者
Raval, Vishal [1 ]
Binkley, Elaine [2 ]
Aronow, Mary E. [3 ]
Valenzuela, Juan [4 ]
Peereboom, David M. [5 ]
Wei, Wei [6 ]
Srivastava, Sunil [1 ]
Davanzo, Jaqueline [1 ]
Boldt, Herbert Culver [2 ]
McGarrey, Mark P. [3 ]
Papaliodis, George N. [3 ]
Sobrin, Lucia [3 ]
Kim, Ivana K. [3 ]
Vavvas, Dimitrios G. [3 ]
Eliott, Dean [3 ]
Nayak, Lakshmi [7 ]
Dodds, Emilio [4 ]
del Pont, Francisco Marco [8 ]
Singh, Arun D. [1 ]
机构
[1] Cleveland Clin, Dept Ophthalm Oncol, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA
[3] Harvard Med Sch, Massachusetts Eye & Ear, Retina Serv, Retina Service, MA USA
[4] Consultores Oftalmol, Dept Retina & Ophthalm Oncol, Buenos Aires, Argentina
[5] Cleveland Clin, Rose Ella Burkhardt Brain Tumor & Neuro Oncol Ctr, Cleveland, OH USA
[6] Cleveland Clin, Dept Quantitat Hlth Sci, Lerner Res Inst, Cleveland, OH USA
[7] Dana Farber Canc Inst, Ctr Neuro Oncol, Boston, MA USA
[8] Fleni, Dept Neurosurg, Buenos Aires, Argentina
来源
EJHAEM | 2022年 / 3卷 / 02期
关键词
inter-compartment; primary central nervous system lymphoma; primary central nervous system lymphoma-ocular variant; primary vitreoretinal lymphoma; progression; treatment; HIGH-DOSE METHOTREXATE; PRIMARY CNS LYMPHOMA; PRIMARY VITREORETINAL LYMPHOMA; PRIMARY INTRAOCULAR LYMPHOMA; INTRAVITREAL METHOTREXATE; INVOLVEMENT; EXPERIENCE; MANAGEMENT; SURVIVAL; THERAPY;
D O I
10.1002/jha2.303
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is limited understanding of the inter-compartmental progression and treatment outcomes of primary central nervous system lymphoma (PCNSL). In this multicenter retrospective cohort study on 234 patients with PCNSL (median age: 62.5 years [18-92]; median follow-up 35 months [0.1-237.0]) from 2000 till 2018 were divided into group 1 (ocular, 44 patients): 1A and 1B without and with CNS progression and group 2 (CNS, 190 patients): 2A and 2B without and with ocular progression, respectively. In group 1 (44 patients), 33 patients received local treatment, and 11 patients received systemic treatment. In group 2 (15 patients), six patients received combination treatment, while seven patients received only systemic treatment. A complete response was observed in 19 (43%) and 91 (48%) patients in groups 1 and 2, respectively. The 2-year progression-free survival (PFS) was 35% (95% CI: 0.23, 0.54) and 56% (95% CI: 0.49, 0.63) for groups 1 and 2, respectively (p < 0.0001). Age < 60 years was significantly associated with longer PFS (median PFS 48 vs. 24 months, p = 0.01). The overall survival (OS) at 2-year was similar among groups 1 and 2 (83% and 67%), respectively (p = 0.06). Thus, Initial compartment of involvement does not influence local response rate or OS.
引用
收藏
页码:362 / 370
页数:9
相关论文
共 30 条
[1]   Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma [J].
Abrey, LE ;
Batchelor, TT ;
Ferreri, AJM ;
Gospodarowicz, M ;
Pulczynski, EJ ;
Zucca, E ;
Smith, JR ;
Korfel, A ;
Soussain, C ;
DeAngelis, LM ;
Neuwelt, EA ;
O'Neill, BP ;
Thiel, E ;
Shenkier, T ;
Graus, F ;
van den Bent, M ;
Seymour, JF ;
Poortmans, P ;
Armitage, JO ;
Cavalli, F .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5034-5043
[2]   High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma [J].
Akiyama, Hiroki ;
Takase, Hiroshi ;
Kubo, Fumito ;
Miki, Tohru ;
Yamamoto, Masahide ;
Tomita, Makoto ;
Mochizuki, Manabu ;
Miura, Osamu ;
Arai, Ayako .
CANCER SCIENCE, 2016, 107 (10) :1458-1464
[3]  
Aronow ME., 2019, Clinical ophthalmic oncology. retinal tumors, P83
[4]  
Aziz Hassan A, 2015, Int Ophthalmol Clin, V55, P111, DOI 10.1097/IIO.0000000000000055
[5]  
Batchelor TT, 2003, CLIN CANCER RES, V9, P711
[6]   Central nervous system relapse of systemic non-Hodgkin's lymphoma: Results of treatment based on high-dose methotrexate combination chemotherapy [J].
Bokstein, F ;
Lossos, A ;
Lossos, IS ;
Siegal, T .
LEUKEMIA & LYMPHOMA, 2002, 43 (03) :587-593
[7]   Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018 [J].
Castellino, Alessia ;
Pulido, Jose S. ;
Johnston, Patrick B. ;
Ristow, Kay M. ;
Bennani, N. Nora ;
Inwards, David J. ;
Macon, William R. ;
Micallef, Ivana N. M. ;
King, Rebecca L. ;
Salomao, Diva R. ;
Witzig, Thomas E. ;
Habermann, Thomas M. ;
Nowakowski, Grzegorz S. .
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) :291-298
[8]   Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium [J].
Chan, Chi-Chao ;
Rubenstein, James L. ;
Coupland, Sarah E. ;
Davis, Janet L. ;
Harbour, J. William ;
Johnston, Patrick B. ;
Cassoux, Nathalie ;
Touitou, Valerie ;
Smith, Justine R. ;
Batchelor, Tracy T. ;
Pulido, Jose S. .
ONCOLOGIST, 2011, 16 (11) :1589-1599
[9]   Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features [J].
Coupland, SE ;
Heimann, H ;
Bechrakis, NE .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2004, 242 (11) :901-913
[10]   Clinical Features Predictive of Survival in Patients With Vitreoretinal Lymphoma: Analysis of 70 Patients at a Single Ocular Oncology Center [J].
Dalvin, Lauren A. ;
Lim, Li-Anne S. ;
Ancona-Lezama, David ;
Mazloumi, Mehdi ;
Chang, Michael ;
Porcu, Pierluigi ;
Martinez, Nina L. ;
Glass, Jon ;
Mashayekhi, Arman ;
Shields, Carol L. .
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2020, 9 (02) :110-116